摘要
目的 探讨血清抗-Survivin抗体、p53抗体在非小细胞肺癌(NSCLC)诊断中的价值。 方法 用酶联免疫吸附(ELISA)检测34例NSCLC患者血清和20例正常健康对照组血清中抗-Sur- vivin抗体、p53抗体水平。结果 有32．35％(11／34)的NSCLC患者血清中有抗-Survivin抗体的出 现,p53抗体阳性者为29．41％(10／34)。20例正常健康对照组血清中无抗-Survivin、p53抗体出现。 结论 血清中抗-Survivin抗体的出现可以作为诊断NSCLC的血清标志物,并有可能作为NSCLC的 早期诊断指标。
Objective To study the diagnostical value on anti-surviving antibodies and 1053 antibody in serum of non-small-cell lung cancer（NSCLC）. Methods Serum levels of anti-survivin antibodies and anti-p53 antibodies in 34 patients with NSCLC and serum levels 20 healthy subjects were measured by Enzyme Linked Immuno Sorbent Assay（ELISA） method. Results Serum levels of anti-survivin anti-bodies and anti-p53 antibodies were much higher in NSCLC than in healthy controls （P=0. 000）. Conclusions Anti-survivin antibodies makes these antibodies an attractive novel marker for the diagnosis of NSCLC.
出处
《贵州医药》
CAS
2005年第11期969-970,共2页
Guizhou Medical Journal
基金
贵州省科技厅自然科学基金资助项目(20023060)贵州省科技厅社会发展基金资助项目(2003036)
